Victory Capital Management Inc. raised its stake in shares of Envista Holdings Co. (NYSE:NVST – Free Report) by 2.3% during the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 36,021 shares of the company’s stock after purchasing an additional 800 shares during the period. Victory Capital Management Inc.’s holdings in Envista were worth $599,000 as of its most recent SEC filing.
Several other hedge funds also recently modified their holdings of the business. Versant Capital Management Inc lifted its holdings in shares of Envista by 1,420.3% during the second quarter. Versant Capital Management Inc now owns 3,147 shares of the company’s stock valued at $52,000 after acquiring an additional 2,940 shares during the period. Quadrant Capital Group LLC increased its position in Envista by 538.0% in the fourth quarter. Quadrant Capital Group LLC now owns 3,209 shares of the company’s stock worth $77,000 after purchasing an additional 2,706 shares during the period. Innealta Capital LLC acquired a new stake in Envista in the second quarter worth about $78,000. Summit Securities Group LLC bought a new position in Envista during the second quarter worth about $85,000. Finally, Signaturefd LLC boosted its holdings in Envista by 85.9% during the second quarter. Signaturefd LLC now owns 5,345 shares of the company’s stock worth $89,000 after buying an additional 2,470 shares during the last quarter.
Envista Stock Performance
NYSE:NVST opened at $19.00 on Monday. The company has a debt-to-equity ratio of 0.47, a current ratio of 2.22 and a quick ratio of 1.90. The business has a fifty day simple moving average of $17.42 and a two-hundred day simple moving average of $18.49. Envista Holdings Co. has a 1 year low of $15.15 and a 1 year high of $28.67. The company has a market capitalization of $3.27 billion, a P/E ratio of -26.39 and a beta of 1.31.
Insider Activity
In other Envista news, CFO Eric D. Hammes acquired 24,532 shares of the company’s stock in a transaction that occurred on Monday, August 12th. The stock was bought at an average price of $16.33 per share, with a total value of $400,607.56. Following the completion of the purchase, the chief financial officer now owns 24,532 shares of the company’s stock, valued at $400,607.56. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. 1.30% of the stock is owned by company insiders.
Wall Street Analysts Forecast Growth
NVST has been the topic of several research reports. Evercore ISI cut their target price on Envista from $19.00 to $18.00 and set an “outperform” rating on the stock in a research note on Thursday, August 8th. Bank of America decreased their target price on Envista from $22.00 to $19.00 and set a “buy” rating on the stock in a report on Thursday, August 8th. JPMorgan Chase & Co. downgraded Envista from an “overweight” rating to a “neutral” rating and cut their target price for the company from $23.00 to $16.00 in a research report on Thursday, August 8th. Stifel Nicolaus dropped their price objective on Envista from $20.00 to $18.00 and set a “buy” rating for the company in a research report on Tuesday, July 30th. Finally, Robert W. Baird lowered their target price on Envista from $19.00 to $17.00 and set a “neutral” rating for the company in a report on Monday, July 22nd. Three equities research analysts have rated the stock with a sell rating, eight have assigned a hold rating and three have given a buy rating to the company. Based on data from MarketBeat, Envista currently has a consensus rating of “Hold” and an average target price of $19.14.
Read Our Latest Analysis on Envista
Envista Profile
Envista Holdings Corporation, together with its subsidiaries, develops, manufactures, markets, and sells dental products in the United States, China, and internationally. The company operates in two segments, Specialty Products & Technologies, and Equipment & Consumables. The Specialty Products & Technologies segment offers dental implant systems, guided surgery systems, biomaterials, and prefabricated and custom-built prosthetics to oral surgeons, prosthodontists and periodontists, and general dentist; and brackets and wires, tubes and bands, archwires, clear aligners, digital orthodontic treatments, retainers, and other orthodontic laboratory products.
Featured Stories
- Five stocks we like better than Envista
- Insider Trading – What You Need to Know
- 3 Stocks That Could Rise on European Bank Interest Rate Cuts
- Stock Analyst Ratings and Canadian Analyst Ratings
- Take Advantage of Village Farms Stock as Cannabis Market Evolves
- 2 Fintech Stocks to Buy Now and 1 to Avoid
- MarketBeat Week in Review – 9/16 – 9/20
Receive News & Ratings for Envista Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Envista and related companies with MarketBeat.com's FREE daily email newsletter.